All AbMole products are for research use only, cannot be used for human consumption.
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) which specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin (up to 10 nM; up to 72 h) can induce cell death in glioma cell lines overexpressing EGFR or EGFRvIII. Depatuxizumab mafodotin (0-3.38 nM; 72 h) induces cell death in a dose-dependent manner in human head and neck squamous cell carcinoma (HNSCC) cell lines (UMSCC47 and FaDu) with high EGFR expression, with IC50 values of 0.213 nM and 0.167 nM for UMSCC47 and FaDu cell lines, respectively.
Immobilized EGFR-P00533-25-645-chis at 2 μg/mL (30 μL/well) can bind Depatuxizumab mafodotin with the EC50 of 19.05 ng/mL.
Depatuxizumab mafodotin (8 mg/kg; i.p.; every 4 days; 6 times in total) causes the loss of EGFRvIII expression in tumors in the orthotopic implantation model of LN-229 EGFRvIII cells in immunodeficient CD1 nude mice. Depatuxizumab mafodotin (4 mg/kg; i.p.; every 4 days; 4 times in total) significantly inhibits tumor growth in female nude mice xenografted with the FaDu cell line.
The drug-to-antibody ratio (DAR) of the Depatuxizumab mafodotin is 4.3.
| Molecular Weight | 148240 |
| CAS Number | 1585973-65-4 |
| Storage | Store at ≤ -20℃ for 24 months. Avoid repeated freeze-thaw cycles. |
| Related Antibody-Drug Conjugates (ADCs) Products |
|---|
| Talacotuzumab-MMAE
Talacotuzumab-MMAE is an antibody-drug conjugate (ADC) targeting IL-3Ra / CD123. Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody. |
| Enfortumab vedotin-ejfv
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate (ADC) for the management of urothelial carcinoma. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE via a protease-cleavable maleimidocaproylvaline-citrulline linker. |
| Vandortuzumab vedotin
Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer. |
| Farletuzumab MMAE
Farletuzumab MMAE is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated to MMAE. |
| Zilovertamab vedotin
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–drug conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
